Transcriptome sequencing of these samples revealed a SLC45A3-SKIL fusion in LuCaP-77 and a MIPEP-SKIL fusion in the clinical sample, confirming SKIL as a recurrent 3′ fusion partner in prostate cancer (Figure 1E-F). Here, SLC45A3 is linked to prostate carcinoma.